Programming - Hypertension Scientific Sessions

September 4–7, 2025
Marriott Baltimore Waterfront | Baltimore, Maryland

Hypertension 2025 Schedule-at-a-Glance

Keep checking this page through the summer as programming is finalized.
Wednesday, Sept. 3 Activities
Time Activity
6:00 pm to 7:00 pm Hypertension Journal Meet the Editors Networking Event
7:00 pm to 9:00 pm Opening Reception and Networking Session
Thursday, September 4 Activities
Time Activity
7:30 am to 8:00 am Welcome and Opening Remarks
8:00 am to 10:00 am Session 1

8:00 to 8:35
Keynote: Overview of the New Hypertension Guidelines

8:35 to 9:35
4 Key Topics in Hypertension Management

9:35 to 10:00
Panel Discussion and Q&A
10:00 am to 10:30 am Break
10:30 am to 12:00 pm Session 2
Concurrent Sessions A, B and C
Invited Lectures followed by Oral Abstract Presentations
12:00 pm to 1:00 pm Session 3
Meet the Guidelines Keynote Speaker and Panel:
Networking Event
1:30 pm to 3:00 pm Session 4

1:30 to 2:00
Harriet Dustan Lecture

2:00 to 3:00
Hypertension Highlights Oral Abstract Presentation
3:00 pm to 3:30 pm Break
3:30 pm to 5:30 pm Session 5

Concurrent Session A & B
Trainee Advocacy Committee Oral Abstract Sessions

Concurrent C
Clinical Science/Clinical Practice Sessions

3:30 to 4:30 p.m.
5C1
Transforming Hypertension Diagnosis and Management with Artificial Intelligence

4:30 to 5:30 p.m.
5C2
Managing Hypertension: From Pregnancy to Postpartum and Beyond

5:30 pm to 7:00 pm Poster Session 1
TAC Poster Session/Competition and Reception
Friday, Sept. 5 Activities
Time Activity
7:00 am to 8:00 am Session 6
Inside the AHA's Research Enterprise: Grant Funding and Other Opportunities
8:00 am to 9:00 am

Session 7
Recent Advances in Hypertension: GLP-1 Agonists

Speakers:
David D'Alessio, MD
Janani Rangaswami, MD, FACP, FAHA
9:00 am to 10:30 am Poster Session 2
With Breakfast Reception
10:30 am to 12:00 pm

Session 8
Concurrent Session A, B
Trainee Advocacy Committee Oral Abstract Sessions

Concurrent Session C
Clinical Science/Clinical Practice track programming
Unpacking the 2025 ACC/AHA Hypertension Guidelines: What’s New and What It Means for Your Practice
12:00 pm to 1:30 pm Session 9
CHAMP Lunch Event
1:30 pm to 3:00 pm Session 10
Concurrent Sessions A and B
Invited Lectures followed by Oral Abstract presentations

Concurrent C
Clinical Science/Clinical Practice Sessions
Rapid-Fire Cases: Burning Questions You’ve Always Wanted to Ask a Hypertension Specialist
3:00 pm to 3:30 pm Break
3:30 pm to 5:30 pm Session 11
Annual Hypertension Awards Session
Includes:
  • The Stephanie Watts Award Finalist presentations
  • Harry Goldblatt Award for New Investigators
  • New Investigator Award for Japanese Fellows
  • Australia and British Irish Awardees
5:30 pm to 6:30 pm

Session 12
The Arthur C. Corcoran Memorial Lecture
The Lewis K. Dahl Memorial Lecture
7:00 pm to 10:00 pm Trainee Advocacy Mixer Event
Saturday, Sept. 6 Activities
Time Activity
7:30 am to 9:00 am Session 13

7:30 to 8:00
The Donald Seldin Lecture

8:00 to 9:00
KCVD Early Career Session
 9:00 am to 10:00 am

Session 14
Concurrent A, B
Oral Abstract Sessions

Concurrent C
CPCS Session
Hypertension Journal CPC Cases

Combining Epithelial Sodium Channel Inhibitor and Mineralocorticoid Receptor Antagonist: Targeted Therapy for Resistant Hypertension in the Young
Vanessa Le
Sarah Lee
Ekamol Tantisattamo, MD

Two cases in Pregnancy: Pheochromocytoma and Paraganglioma
Bernadette Jenner
Ian Wilkinson

10:00 am to 10:30 am Break 
10:30 am to 12:00 pm Session 15
Concurrent A, B and C
Invited Lectures followed by Oral Abstract Presentations
12:00 pm to 1:30 pm Lunch on Your Own 
1:30 pm to 3:00 pm

Session 16
Concurrent Sessions A and B
Invited Lectures followed by Oral Abstract presentations

Concurrent Session C
Primary Care track sessions
Hypertension Across the Lifespan
3:00 pm to 3:30 pm  Break 
3:30 pm to 5:30 pm

Session 17

3:30 to 4:30
Council On Hypertension Mid-Career Award for Research Excellence
Council on Kidney in Cardiovascular Disease Mid-Career Acheivement Award

4:30-5:30
Concurrent Sessions A and B
Oral Abstract Sessions

Concurrent C
Primary Care Track Sessions

3:30 – 4:30 p.m.
17C1
Beyond Office, Seated Blood Pressure: How to Interpret Atypical BP Data

4:30 – 5:30 p.m.
17C2
Rethinking the Box: When Using Less Traditional Blood Pressure Reduction Strategies Delivers More
5:45 pm to 6:15 pm Session 18
Excellence Award for Hypertension Research Lecture
7:00 pm to 10:00 pm Council Awards Banquet
(Ticketed Event) 
Sunday, Sept. 7 Activities
Time Activity
8:00 am to 9:30 am

Session 19
Concurrent Session A and B
Invited lectures followed by Oral Abstract Presentations

Concurrent C
Primary Care Track Sessions

19C1
8:00 – 8:45 a.m.
My Top Clinical-Practice Changing Papers this Year

19C2
8:45- 9:30 AM
Debate: Efficiency in BP Measurement: Perfect is the Enemy of the Good?

9:30 am to 10:00 am Break
10:00 am to 11:30 am Session 20
Concurrent Sessions A, B and C
 Invited lectures followed by oral abstract presentations
11:30 am to 12:00 pm Closing Keynote Lecture
 R. Ariel Gomez, MD, FAHA

About This Meeting

Hypertension 2025 Scientific Sessions is considered the premier scientific meeting on the subject in the world. A collaborative effort between the Council on Hypertension and the Council on the Kidney in Cardiovascular Disease, the science submitted to this conference continues to bring us the most up to date developments on our understanding of: the causes of hypertension; its relationship to stroke, cardiac disease and kidney dysfunction; and the most effective means for detecting, evaluating and treating high blood pressure across diverse populations.

This year's programming also includes:

  • Recent Advances sessions and lectures on cutting-edge science, followed by oral abstract presentations
  • Clinical Science/Clinical Practice track
  • Primary Care track
  • Oral abstract sessions highlighting Early Career oral abstract presentations
  • Networking sessions
  • Trainee Advocacy Committee (TAC) Poster session and competition
  • Award Lecture sessions

Learning Objectives

  1. Discuss recent advances and emerging experimental models in hypertension and kidney disease.
  2. Summarize findings from recent clinical trials and the impact on future treatment and/or management of hypertensive and kidney-related disorders.
  3. Describe new therapeutic options and technologies for patients with hypertension and kidney disease.
  4. Describe the most up-to-date clinical guideline recommendations for the prevention, diagnosis, and management of hypertension and kidney disease.